Stocktoria
CYTOKINETICS INC CYTK
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2004-04-29
CYTOKINETICS INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $88.0M | $18.5M | $7.5M | $94.6M | $70.4M |
| R&D expense | $416.0M | $339.4M | $330.1M | $240.8M | $159.9M |
| Operating income | -$612.3M | -$536.2M | -$496.2M | -$324.2M | -$186.3M |
| Interest expense | $45.6M | $37.7M | $28.3M | $19.4M | $16.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$785.0M | -$589.5M | -$526.2M | -$389.0M | -$215.3M |
| EPS (diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
| Operating cash flow | -$510.0M | -$395.9M | -$414.3M | -$299.5M | -$142.5M |
| Free cash flow | -$534.8M | -$399.8M | -$415.7M | -$310.9M | -$191.4M |
| Cash & equivalents | $122.5M | $94.9M | $113.0M | $65.6M | $112.7M |
| Inventory | $0 | — | — | — | — |
| Total assets | $1.4B | $1.4B | $824.3M | $1.0B | $841.3M |
| Total liabilities | $2.1B | $1.5B | $1.2B | $1.1B | $597.5M |
| Shareholders' equity | -$659.6M | -$135.4M | -$386.3M | -$107.9M | $243.9M |
Source: SEC EDGAR filings · CIK 0001061983 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.